An entirely reasonable post. Not sure of the relevance of the other letter to Mr Lassman.
No obvious relationship to the Remestemcel BLA? Although in broad terms it does refer to the reasons for denying approval of a new drug according to the FDA's protocols regarding assesment of safety and efficacy.
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-999
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 99.0¢ | $1.03 | 97.0¢ | $2.815M | 2.838M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 151781 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 80522 | 1 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |